Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results front a multicenter prospective randomized trial

Breast Cancer Research and Treatment

Volumn 49, Issue 3, 1998, Pages 209-217

  Amadori, Dino ^a   Frassineti, Giovanni Luca ^a   De Matteis, Andrea ^b   Mustacchi, Giorgio ^c   Santoro, Antonio ^d   Cariello, Salvatore ^e   Ferrari, Massimo ^f   Nascimben, Ottorino ^g   Nanni, Oriana ^h   Lombardi, Alessandra ^h   Scarpi, Emanuela ^h   Zoli, Wainer ^a  

^a Ospedale Pierantoni   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d San Gennaro Hospital   (Italy)

^e Ospedale S Leonardo   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g Ospedale Umberto I   (Italy)

^h ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

Advanced breast cancer; Doxorubicin; Lonidamine

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; LONIDAMINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG HYPERSENSITIVITY; EPIGASTRIC PAIN; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL PROTOCOLS; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HUMANS; INDAZOLES; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 7344255198     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006063412726     Document Type: Article

References (50)

1. Tormey DC: Adriamycin in breast cancer. Cancer Chemother Rep (Part 3) 6: 319-327, 1975
2. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3 (6): 818-826, 1985
3. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9: 2148-2152, 1991
4. Cowan JD, Neidhart J, Mc Clure S, Coltman CA, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin, bisanthrene, and mitoxantone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83: 1077-1084, 1991
5. Jones S, Durie BG, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36: 90-97, 1975
6. Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, Perlin E, Simon R: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41 (5): 1649-1657, 1978
7. Decker DA, Ahman DL, Bisel HF, Edmonson JH, Hahn RG, O'Fallon JR: Complete responders to chemotherapy in metastatic breast cancer: Characterization and analysis. JAMA 242: 2075-2079, 1979
8. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, Buzdar AU, Tashima CK, Burgess MA, Hersh EM: Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole. Cancer 43 (3): 1112-1122, 1979
9. Rosner D: A comparison of intermittent vs continuous: Optimal sequential chemotherapy for metastatic breast cancer. NY Med Q: 6-15, 1981
10. Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 305: 139-153, 1981
11. Nemoto T, Horton J, Simon R, Dao TL, Rosner D, Cunningham T, Sponzo R, Snyderman M: Comparison of four-combination chemotherapy programs in metastatic breast cancer. Cancer 49: 1988-1993, 1982
12. Smalley R, Gams R: Phase II study of mitoxantrone in patients with metastatic breast carcinoma: A Southeastern Cancer Study Group project. Cancer Treat Rep 67: 1039-1040, 1983
13. Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three? Breast Cancer Res Treat 3: 117-127, 1983
14. Zekan PJ, Muss HB, Capizzi RL, Cooper MR, Harding RW, Hopkins JO, Jackson DV, Ramseur WL, Richards F, Spurr CL, Stuart JJ, White DR, Pope H, Case LD, Wells HB: High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin and cyctophosphamide in advanced carcinoma of the breast: A phase III study of the Piedmont Oncology Association (POA). Cancer 54 (11): 2338-2343, 1984
15. Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, Weiss RB, Aisner J: A comparison of intermittent versus continuous and adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7: 231-239, 1984
16. Cummings FJ, Gelman R, Horton J: Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors. J Clin Oncol 3: 932-940, 1985
17. Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, Falkson HC: The Eastern Cooperative Oncology Group study experience with cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219-224, 1985
18. Ahmann DL, Schaid DJ, Ingle JN, Bisel HF, Schutt AJ, Buckner JC, Long HJ, Rubin J: A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol 14 (3): 179-183, 1991
19. Pastan I, Gottesman MM: Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393, 1987
20. Bellamy WT, Dalton WS, Dorr RT: The clinical relevance of multidrug resistance. Cancer Invest 8 (5): 547-562, 1990
21. Hayes JD, Wolf CR: Molecular mechanisms of drug resistance. Biochem J 272: 281-295, 1990
22. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 53: 747-754, 1993
23. Hait WN: Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 43: 103-107, 1992
24. Fitzgerald DJ, Willingham MC, Cardarelli CO, Hamada H, Tsuruo T, Gottesman MM, Pastan I: A monoclonal antibody pseudomonas toxin conjugate that specifically kills multidrug resistant cells. Proc Natl Acad Sci 84 (12): 4288-4292, 1987
25. Thierry AR, Rahman A, Dritschilo A: Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotide. Biochem Biophys Res Commun 15: 952-960, 1993
26. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. JNCI 66: 497-499, 1981
27. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41: 4661-4666, 1981
28. Floridi A, Lehninger AL: Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys 226: 73-83, 1983
29. Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B, Poupon MF: Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62: 216-222, 1995
30. Ben Horin H, Tassini M, Vivi A, Navon G, Kaplan O: Mechanism of action of the antineoplastic drug lonidamine: 31 P and 13 C nuclear magnetic resonance studies. Cancer Res 55: 2814-2821, 1995
31. Floridi A, Gambacurta A, Bagnato A, Bianchi C, Paggi MG, Silvestrini B, Caputo A: Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells. Exp Mol Pathol 49: 421-431, 1988
32. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A: In vitro and in vivo potentiation by lonidumine of the antitumor effects of adriamycin. Anticancer Res 6: 1245-1250, 1986
33. Savini S, Zoli W, Nanni O, Volpi A, Frassineti GL, Magni E, Flamigni A, Amadori A, Amadori D: In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 24: 27-34, 1992
34. Citro G, Cucco C, Verdina A, Zupi G: Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64: 534-536, 1991
35. Del Bufalo D, Zupi G: In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell line. Int J Oncol 4: 737-740, 1994
36. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52: 813-817, 1992
37. Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E: Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 25: 32-36, 1989
38. Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu S, Frei E III: Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res 51: 780-784, 1991
39. Schwartz GN, Teicher BA, Eder JP Jr, Korbut T, Holden SA, Ara G, Herman TS: Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemother Pharmacol 32: 455-462, 1993
40. Ning S, Hahn GM: Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT 1080 cells in vitro. Cancer Res 50: 7867-7880, 1990
41. Villa R, Zaffaroni N, Orlandi L, Bearzatto A, Costa A, Silvestrini R: In vitro effect of lonidamine on the cytotoxicity of mitomycin-C and BCNU in human colon adenocarcinoma cells. Eur J Cancer 30: 1534-1540, 1994
42. Zupi G, Molinari A, D'Agnano I, Meschini S, Del Bufalo D, Matarrese P, Candiloro A, Calcabrini A, Citro G, Arancia G: Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. Anticancer Res 15: 2469-2478, 1995
43. World Health Organization: WHO Handbook for Reporting the Results of Cancer Treatment. WHO offset publication n. 48, Geneva, Switzerland, UICC, 1979
44. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958
45. SAS Institute Inc. SAS/STAT User's Guide, version 6, 4th edn, vol. 1. Cary, NC: SAS Institute Inc., 1989, p 943
46. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Alquati P, Doltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D: Lonidamine significantly increases the activity of epirubicin in advanced breast cancer patients. Results from a multicenter prospective randomized trial. J Clin Oncol 14 (4): 1165-1172, 1996
47. Calabresi F, Marolla P, Di Lauro L, Gallo Curcio C, Paoletti G, Lombardi A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, Stolfi R, Cortesi E: Lonidamine (LND) as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. Int J Oncol 4: 753-760, 1994
48. Tomirotti M, Bernardo G, Epifani C, Biasioli R, Franchi R, Mensi F, Carnaghi P, Schieppati G, Scanni A: Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 3: 213-217, 1993
49. Lopez M, Via P, Di Lauro L, Paoletti G, Giontra T, Conti F, Carpano S, Pignatti F, Giannarelli D: Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. Eur J Cancer 31A (10): 1611-1614, 1995
50. Besner JG, Leclaire R, Band PR, Deschamps M, De Sanctis AJ, Catanese B: Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 41 (1): 48-52, 1984